Shanghai Junshi Biosciences (HKG:1877, SHA:688180) will conduct clinical trials on JS212 injection after receiving approval from China's National Medical Products Administration, according to a Hong Kong Stock Exchange disclosure on Thursday.

The drug will be tested as a treatment for advanced malignant solid tumors in conditions such as lung cancer, breast cancer, and head and neck cancer, the pharmaceutical company said.

Junshi Bio's Hong Kong shares dropped over 4% and Shanghai shares fell less than 2% in recent trade.